- Reproductive risk factors associated with breast cancer in young women by molecular subtype.
- Ruddy KJ, Vierkant RA, Jahan N, Higgins A, Partridge A, Larson N, Radisky DC, Couch F, Olson J, Sherman ME.
- Breast. 2022 Nov 9:S0960-9776(22)00187-4. doi: 10.1016/j.breast.2022.11.004. Epub ahead of print.
- Using a machine learning algorithm to predict outcome of primary cytoreductive surgery in advanced ovarian cancer.
- Piedimonte S, Erdman L, So D, Bernardini MQ, Ferguson SE, Laframboise S, Bouchard Fortier G, Cybulska P, May T, Hogen L.
- J Surg Oncol. 2022 Nov 9. doi: 10.1002/jso.27137. Epub ahead of print.
- PMID: 36350138
- PubMed abstract
- Source abstract
- Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
- Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, Alarcón J, Calzas J, Gaba L, Fuentes J, Santaballa A, Salvador C, Manso L, Herrero A, Taus Á, Márquez R, Madani J, Merino M, Marquina G, Casado V, Constenla M, Gutiérrez M, Dosil A, González-Martín A.
- BMC Cancer. 2022 Nov 8;22(1):1150. doi: 10.1186/s12885-022-10191-5.
- PMID: 36348385
- PubMed abstract
- NBN pathogenic germline variants are associated with pan-cancer susceptibility and in vitro DNA damage response defects.
- Belhadj S, Khurram A, Bandlamudi C, Palou-Márquez G, Ravichandran V, Steinsnyder Z, Wildman T, Catchings A, Kemel Y, Mukherjee S, Fesko B, Arora K, Mehine M, Dandiker S, Izhar A, Petrini J, Domchek S, Nathanson KL, Brower J, Couch F, Stadler Z, Robson M, Walsh M, Vijai J, Berger M, Supek F, Karam R, Topka S, Offit K.
- Clin Cancer Res. 2022 Nov 8:CCR-22-1703. doi: 10.1158/1078-0432.CCR-22-1703. Epub ahead of print.
- PMID: 36346689
- PubMed abstract
- Source abstract
- Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
- Washington CR, Moore KN.
- Curr Oncol Rep. 2022 Nov 8. doi: 10.1007/s11912-022-01337-6. Epub ahead of print.
- PMID: 36346509
- PubMed abstract
- Source abstract
- Review
- Study: More is not better: PARP dose can be safely reduced for people with ovarian cancer.
- [No author given]
- FORCE. XRAY. 2022 Nov 8.
- Research news
- Free Full Text
•• Original research:
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
- PMID: 35219776
- PubMed abstract
- Source abstract
- Tests to Guide PARP Inhibitors Emerge as New Focus for Public-Private Harmonization Effort.
- Ashford K.
- Precision Oncology News. 2022 Nov 8.
- News